EP Patent

EP3085387A1 — Sparc binding antibodies and uses thereof

Assigned to Abraxis Bioscience LLC · Expires 2016-10-26 · 10y expired

What this patent protects

The invention provides SPARC binding antibodies that target disease sites, in particular, tumors and uses thereof to diagnose and treat diseases, in particular, cancerous tumors.

USPTO Abstract

The invention provides SPARC binding antibodies that target disease sites, in particular, tumors and uses thereof to diagnose and treat diseases, in particular, cancerous tumors.

Drugs covered by this patent

Patent Metadata

Patent number
EP3085387A1
Jurisdiction
EP
Classification
—
Expires
2016-10-26
Drug substance claim
No
Drug product claim
No
Assignee
Abraxis Bioscience LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.